Evidence & Outcomes
Proof, not adjectives
Every figure on this page is measured against a stated baseline, not written for a pitch deck. Here's what we measured, what it's compared to, and what's still being finalised for external citation.
−
Unplanned readmissions, HF cohort, 6-month RCT
Patients cared for
Days of monitored care
Cardiac rehabilitation completion
Does it keep people out of hospital?
Heart-failure patients on TCC saw 49% fewer unplanned hospital readmissions over 6 months versus standard care — 21 events vs 41 — in a peer-reviewed pilot randomised controlled trial of 164 patients across two Sydney sites.
Indexed unplanned readmissions, HF cohort, 6-month RCT · standard care = 100
The trial's primary endpoint — readmissions at 30 days — was neutral (11 in both arms). We're stating that plainly rather than citing only the endpoint that flatters the result: the effect showed up over the longer, 6-month follow-up window instead, alongside gains in medication adherence and cardiac rehabilitation completion below.
Does it change what patients actually do?
A 2× improvement in cardiac rehabilitation completion among monitored patients — 39% vs 18% in the same trial — alongside higher medication adherence, 75% vs 50%.
Cardiac rehabilitation completion, same RCT cohort
Cardiac rehabilitation completion and medication adherence, compared between the TCC and standard-care arms of the same trial.
Has it run at real scale?
10,000+ patients monitored across 28,000+ cumulative days of care, in live clinical services — not a pilot cohort.
Methodology & sources
The readmission and rehabilitation figures above come from a peer-reviewed, two-site pilot randomised controlled trial of 164 patients discharged after acute coronary syndrome or heart failure, run in partnership with UNSW and South Eastern Sydney Local Health District (2022). Scale figures (10,000+ patients, 28,000+ days of monitored care) reflect Apostele's live TeleClinical Care deployment to date, including the program's ongoing use within SESLHD's Community Management Centre.
A larger, fully-powered multicentre trial of over 1,000 patients across New South Wales ("TCC-Cardiac") is already planned as the next step in this program — we're not stopping at a pilot. Full citation details are being finalised for publication on this page; ask for the underlying papers directly in a demo in the meantime.
Research & deployment partners
UNSW Sydney
Research & validation partner
SESLHD
Health-district deployment partner
Tyree Foundation Institute of Health Engineering
UNSW research institute, co-directed by Nigel Lovell
See the data in context.
A 30-minute walkthrough of the platform, the alert logic, and the evidence behind it.